SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

ABBV-1480

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
If Phase 3 succeeds, potential regulatory filing would be around 2029-2030 based on the estimated December 2029 primary completion date of the pivotal trial.
Why 3/10
No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled within the next ~12 months. The Phase 3 AMUR-Lung-01 trial began recruiting in September 2026 with estimated primary completion in December 2029. For a large-cap diversified pharma like AbbVie, this single mid-stage asset represents a small fraction of enterprise value.
Actionable Insight NEUTRAL

The next hard catalyst for ABBV-1480 is the Phase 3 AMUR-Lung-01 (NCT07756645) data readout, but with estimated primary completion in December 2029, no binary event is expected within the next 12 months. Watch for interim analysis announcements, expansion into additional solid tumor indications, and any early efficacy signals from the ongoing Phase 3 enrollment. For a company of AbbVie's size, this is one of many pipeline assets and not a near-term value driver.

Price Chart

Loading chart...

Executive Summary

ABBV-1480 (RC148) is an investigational PD-1/VEGF bispecific antibody being developed by AbbVie (ABBV) under a January 2026 licensing deal with RemeGen that included a $650M upfront payment and up to $4.95B in milestones. Phase 1b data presented at WCLC 2026 showed a 90% objective response rate in first-line squamous NSCLC when combined with chemotherapy, and ESMO 2026 data showed 61.9% ORR as monotherapy in PD-L1-positive NSCLC. A global Phase 3 trial (AMUR-Lung-01, NCT07756645) comparing ABBV-1480 plus chemo against Keytruda plus chemo in 940 patients began recruiting in September 2026 with estimated completion in December 2029. For AbbVie, a $295B+ market cap diversified pharma, ABBV-1480 is one of many pipeline assets with no near-term binary catalyst.

How It Works

ABBV-1480 is a bispecific antibody, a single engineered molecule designed to hit two targets at once. It blocks PD-1 (a brake on immune cells that tumors exploit to hide) and VEGF (a protein tumors use to grow blood vessels for their own supply). By disabling both pathways simultaneously, the drug aims to let the immune system attack the tumor while cutting off its blood supply. Its design uses a VEGF-triggered enrichment mechanism that may concentrate the drug in the tumor area and reduce side effects compared to giving two separate drugs.

Trial Status

The global Phase 3 AMUR-Lung-01 trial (NCT07756645) began recruiting in September 2026, comparing ABBV-1480 plus platinum-based chemotherapy against pembrolizumab (Keytruda) plus chemotherapy as first-line treatment for advanced/metastatic non-small cell lung cancer, targeting 940 participants. Phase 1b data in 1L NSCLC and Phase 1 monotherapy data in PD-L1-positive NSCLC were presented at WCLC 2026 and ESMO 2026, respectively. A combination study with AbbVie's c-Met ADC Temab-A in NSCLC (NCT07874282) has also been initiated.

The Two-Sided Case

▲ Bull Case5
Phase 1b data showed a 90.0% objective response rate in squamous NSCLC and 75.9% in non-squamous NSCLC when combined with platinum-based chemotherapy at the recommended Phase 3 dose (10 mg/kg), a strong early signal.
ESMO 2026 data showed ABBV-1480 monotherapy achieved a 61.9% ORR and 15.2-month median PFS in first-line PD-L1-positive NSCLC (n=22), supporting its potential as a monotherapy option.
The differentiated tetravalent design uses VEGF-triggered tumor enrichment, which may reduce systemic anti-VEGF toxicity compared to competitors like ivonescimab.
AbbVie has deep pockets and extensive oncology commercial infrastructure, giving ABBV-1480 strong development and launch resources if Phase 3 succeeds.
AbbVie is also exploring combination with its c-Met ADC Temab-A in NSCLC (NCT07874282), potentially creating a differentiated franchise.
▼ Bear Case5
ABBV-1480 is entering a crowded PD-1/VEGF bispecific field where ivonescimab (Summit/Akeso) and pumitamag are already advanced, and Keytruda (pembrolizumab) is the entrenched standard of care in 1L NSCLC.
Phase 1b data (90% ORR in squamous NSCLC) comes from small sample sizes (n=30 squamous, n=29 non-squamous) and may not replicate in the large Phase 3 trial.
AbbVie paid $650M upfront plus up to $4.95B in milestones for ex-China rights, a large bet on an asset that was still in Phase 2 in China at deal signing, with no guarantee of regulatory success.
The Phase 3 AMUR-Lung-01 trial (n=940) is head-to-head against Keytruda, which has a multi-billion dollar established efficacy and safety track record, setting a high bar for non-inferiority or superiority.
ABBV-1480 is a small part of AbbVie's massive pipeline; even strong data would have a limited impact on AbbVie's stock price given the company's diversified revenue base.

Upcoming Catalysts

  • Phase 3 AMUR-Lung-01 interim analysis (no date announced; trial estimated to complete Dec 2029)
  • Expansion into additional solid tumor indications beyond NSCLC
  • Potential partnership or combination study updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 10

Hover a chip for the title
1 news.abbvie.com2 biopharminternational.com3 news.abbvie.com4 news.abbvie.com5 clinicaltrials.gov6 fiercebiotech.com7 onclive.com8 pryzm.ozmosi.com9 remegen.com10 trialticker.com